<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058070</url>
  </required_header>
  <id_info>
    <org_study_id>1306</org_study_id>
    <nct_id>NCT01058070</nct_id>
  </id_info>
  <brief_title>An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter</brief_title>
  <official_title>An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torax Medical Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torax Medical Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic Esophageal Sphincter implant is intended to reinforce Esophageal Sphincter function
      in the treatment of Gastroesophageal Reflux Disease (GERD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this feasibility study is to collect preliminary performance and safety
      information and develop procedural optimization for the Torax Medical Inc. Magnetic
      Esophageal Sphincter device (MES) in reinforcement of Esophageal Sphincter function to treat
      Gastroesophageal Reflux Disease (GERD). The information from this study will be used to
      support the design and conduct of an expanded clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate the Incidence of All Adverse Events at Various Time Points.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To Monitor the Improvement of GERD Symptoms.</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of participants with a 50% or more reduction in total GERD-HRQL score is indicative of a substantial improvement in GERD symptoms</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Implantable Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Torax Medical, Inc. LINX Reflux Management System</intervention_name>
    <description>Implantable device, Magnetic Esophageal Sphincter</description>
    <arm_group_label>Implantable Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years, &lt; 85 years, life expectancy &gt; 3yrs.

          -  Documented history of GERD symptoms such as heartburn and/or regurgitation.

          -  On daily PPI treatment for at least 3-months.

          -  Responsive to PPI treatment.

          -  GERD symptoms, in absence of PPI therapy (minimum 10 days).

          -  Ambulatory Esophageal pH &lt; 4 for ≥ 5% time or pH &lt; 4 for ≥ 3% time in supine position.

          -  Patient is a surgical candidate.

          -  Patient is willing and able to cooperate with follow-up examinations.

          -  Patient has been informed of the study procedures and the treatment and has signed an
             informed consent form and provided authorization to use and disclose information for
             research purposes (HIPAA).

        Exclusion Criteria:

          -  The procedure is an emergency procedure.

          -  Patient is currently being treated with another investigational drug or
             investigational device.

          -  Patient has had prior gastric or esophageal surgery.

          -  Patient has had any previous endoscopic intervention for GERD

          -  Patient has suspected or confirmed esophageal or gastric cancer.

          -  Patient has any size paraesophageal hiatal hernia or sliding hiatal hernia ≥3cm.
             (Investigator to identify and record type of hiatal hernia at the time of assessment
             (i.e. para-esophageal, sliding)).

          -  Patient's esophageal motility is less than 35 mmHg peristaltic amplitude on wet
             swallows or &gt; 30% failed (non-propulsive) peristaltic sequences.

          -  Patient has esophagitis - Grade B, C, D (LA Classification).

          -  Patient has Barretts Esophagus.

          -  Patient has BMI &gt; 35.

          -  Patient has symptoms of dysphagia or indications of dysphagia from barium esophagram.

          -  Patient has Scleroderma and/or Achalasia.

          -  Patient has an esophageal stricture or gross esophageal anatomic abnormalities
             (obstructive lesions, etc.).

          -  Patient has an electrical implant or metallic, abdominal implant(s).

          -  Patient cannot understand trial requirements or is unable to comply with follow-up
             schedule.

          -  Patient is pregnant or nursing, or plans to become pregnant.

          -  Patient has a psychiatric disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ganz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Gastroenterolgy, PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chapman Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <results_first_submitted>March 3, 2014</results_first_submitted>
  <results_first_submitted_qc>May 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2014</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Implantable Device</title>
          <description>Torax Medical, Inc. LINX Reflux Management System: Implantable device, Magnetic Esophageal Sphincter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Implantable Device</title>
          <description>Torax Medical, Inc. LINX Reflux Management System: Implantable device, Magnetic Esophageal Sphincter</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" lower_limit="19.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" lower_limit="19.0" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% time esophageal pH&lt;4</title>
          <description>The time during which esophageal pH is less than 4.0 divided by the total recording time expressed in percentage.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" lower_limit="2.7" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL)</title>
          <description>Scoring scale is from 0 to 5 with 0=no symptoms to 5=symptoms are incapacitating. The maximum value score is 50.</description>
          <units>scores on a scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate the Incidence of All Adverse Events at Various Time Points.</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LINX Study Subjects</title>
            <description>Subjects implanted with LINX device</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Incidence of All Adverse Events at Various Time Points.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Monitor the Improvement of GERD Symptoms.</title>
        <description>Percentage of participants with a 50% or more reduction in total GERD-HRQL score is indicative of a substantial improvement in GERD symptoms</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Implantable Device</title>
            <description>Torax Medical, Inc. LINX Reflux Management System: Implantable device, Magnetic Esophageal Sphincter</description>
          </group>
        </group_list>
        <measure>
          <title>To Monitor the Improvement of GERD Symptoms.</title>
          <description>Percentage of participants with a 50% or more reduction in total GERD-HRQL score is indicative of a substantial improvement in GERD symptoms</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Implantable Device</title>
          <description>Torax Medical, Inc. LINX Reflux Management System: Implantable device, Magnetic Esophageal Sphincter</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting &amp; Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting &amp; Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Stomach bloating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Inability to belch or vomit</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>No improvement</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Device explant/reoperation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP of Clinical Affairs</name_or_title>
      <organization>Torax Medical, Inc.</organization>
      <phone>651-361-8900</phone>
      <email>aderosier@toraxmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

